Ann: Notice of Annual General Meeting/Proxy Form, page-6

From what I can gather after reading/watching those posts @aburbe (thanks for posting btw, good stuff) is that BOT are skimming the top of a much larger 'berg' in terms of possible treatment targets they might look at developing in the future.........

What a great place to be..........with so much untapped science and medical application waiting to be investigated.

The current pipeline is fantastic for sure, each individual product has company maker potential imo, but there are undoubtedly further novel applications yet to be realized in numerous treatment areas.

Where we have some serious added clout (as if we needed it)...........Permetrex™ exclusivity......... (exceptional advantage to be had here I believe). 

"Novel skin delivery system -Permetrex™ - greatly improves delivery of drug to the skin compared to traditional approaches"

"Permetrex delivers much more cannabidiol (CBD) into the target layers of the skin, even though the CBD concentration of the BTX 1503 formulation is only ¼ to ½ the concentration of alternative formulations".

"In two of the common antibiotic resistant bacteria strains, Permetrex™ significantly improves the killing power of cannabidiol, to achieve close to 100% bacteria killing effect (at low concentrations)".

It would certainly seem we have a just a smidgen  of '1st mover' type advantage at this point re clinically investigating CBD based derma treatment applications.......(we're the only one out of 138 trials to be investigating the derma side of the CBD coin???? Crazy stuff, seriously I still can't believe that).

Fully funded for two complete phase 2 clinical trials with further pipeline products also funded for progression......as biotechs go BOT is an absolute standout in the space as far as I'm concerned.